Răzvana Sorina Munteanu-Dănulescu

Răzvana Sorina Munteanu-Dănulescu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2024 in Romanian Journal of Ophthalmology
Verified
Journal Article
Open access
RIRaluca Eugenia Iorga
Raluca Eugenia Iorga
RMRăzvana Sorina Munteanu-Dănulescu
Răzvana Sorina Munteanu-Dănulescu
CDCiprian Danielescu
Ciprian Danielescu
Leber’s hereditary optic neuropathy (LHON) is the most common maternally inherited disease linked to mitochondrial DNA (mtDNA). The patients present with subacute asymmetric bilateral vision loss. Approximately 95% of the LHON cases are caused by m.3460G>A (MTND1), m.11778G>A (MTND4), and m.14484T>C (MTND6) mutations. The hallmark of hereditary optic neuropathies determined by mitochondrial dysfunction is the vulnerability and degeneration of retinal ganglion cells (RGC). We present the case of a 28-year-old man who came to our clinic complaining of a subacute decrease in visual acuity of his left eye. From his medical history, we found out that one month before he had the same symptoms in the right eye. From the family history, we noted that an uncle has had vision problems since childhood. We carried out complete blood tests, including specific antibodies for autoimmune and infectious diseases. Laboratory tests and MRI were within normal limits. A blood test of the mtDNA showed the presence of 11778 G>A mutation on the mtND6 gene. The medical history, the fundus appearance, the OCT, and the paraclinical investigations, made us diagnose our patient with Leber’s hereditary optic neuropathy. As soon as possible, we began the treatment with systemic idebenone, 900 mg/day. We examined the patient 2, 6, and 10 weeks after initiating the treatment.

23 July 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
RIRaluca-Eugenia Iorga
Raluca-Eugenia Iorga
Vlad Constantin DonicaVlad Constantin Donica
Vlad Constantin Donica
Ciprian DanielescuCiprian Danielescu
Ciprian Danielescu
Camelia Margareta BogdaniciCamelia Margareta Bogdanici
Camelia Margareta Bogdanici
RMRăzvana Sorina Munteanu-Dănulescu
Răzvana Sorina Munteanu-Dănulescu
AMAndreea Dana Moraru
Andreea Dana Moraru
Background: The eye provides a valuable window for the identification of neurological diseases, as pathological changes may involve both the retina and the optic nerve. Standard imaging of the retina and the optic nerve are non-invasive and are useful tools in investigating the integrity of the visual pathways. With population aging and the increasing burden of neuro-ophthalmic diseases, there is a growing need for tools that can assist clinicians in achieving rapid and reliable diagnoses. AI may facilitate the detection of specific neuro-ophthalmological conditions. Methods: This article presents a narrative review of previously published studies addressing the current applications of AI in selected neuro-ophthalmic conditions, with emphasis on their advantages, limitations, and challenges in screening, diagnosis, and disease progression assessment. Results: AI-based approaches provide valuable opportunities for the screening, characterization, and monitoring of optic nerve head abnormalities in neuro-ophthalmology. Recent advancements, particularly in deep learning and convolutional neural networks, have shown notable potential in interpreting fundus photography, optical coherence tomography and magnetic resonance imaging, supporting a comprehensive assessment of optic nerve structure and function. These systems are particularly promising because they can extract quantitative information from routine imaging modalities and may assist clinicians in detecting structural damage that is difficult to identify through conventional evaluation alone. Conclusions: AI-assisted ophthalmic imaging has shown promising diagnostic performance in identifying ONH abnormalities and retinal or optic nerve changes associated with neurological disease. At present, however, most applications remain within research, retrospective validation, or proof-of-concept settings, and evidence that AI consistently improves early diagnosis or clinical outcomes beyond conventional assessment remains limited. Accordingly, AI should currently be regarded as a complementary tool that may support screening, image interpretation, disease characterization, and referral decisions rather than replace established clinical evaluation.

23 July 2025 in Life
Verified
Journal Article
Open access
PDF file
RIRaluca Eugenia Iorga
Raluca Eugenia Iorga
AMAndreea Dana Moraru
Andreea Dana Moraru
RMRăzvana Sorina Munteanu-Dănulescu
Răzvana Sorina Munteanu-Dănulescu
Delia UrdeaDelia Urdea
Delia Urdea
Ciprian DanielescuCiprian Danielescu
Ciprian Danielescu
The aim of this paper is to present our experience with the diagnosis and management of nine patients diagnosed with Leber’s hereditay optic neuropathy. Materials and methods: We conducted a prospective, observational study that included nine patients treated with idebenone, followed for a period of 18 months. Results: Our findings suggest that the impact of treatment varies significantly depending on the disease phase. In the acute phase, visual acuity deteriorated from 0.67 logMAR at onset to 0.97 logMAR at 3 months, followed by a slight improvement to 0.88 logMAR at 9 months. In the chronic phase, average values decreased progressively from 1.44 logMAR at onset to 1.26 logMAR at 12 and 18 months. We also observed a consistent treatment benefit over time in eyes harbouring the m.11778 G > A mutation. Although the most powerful predictor of visual outcome remains the mtDNA genotype, young age at onset is correlated with a better prognosis. In the acute phase, more cases of a clinically relevant benefit were observed than expected (33.33% versus 22.22% expected), and fewer clinically relevant worsening cases were observed (0% versus 11.11% expected). Regarding OCT measurement, our study highlighted a significant difference in peripapillary retinal nerve fiber layer thickness between the initial evaluation and the 6-month follow-up (100.83 µm ± 30.2 at baseline versus 96.7 µm ± 24.8 at 6 months). Conclusions: Our paper demonstrates the benefit of idebenone treatment in improving visual acuity in patients with Leber hereditary optic neuropathy. We highlighted the importance of long-term treatment, emphasizing that extended administration is key to achieving favorable outcomes.